Selatogrel P2Y12 SC ACS self-administered investigational

Selatogrel Patient Guide: How to Get Selatogrel at Low or No Cost

Important Notice: Selatogrel is an investigational drug still in Phase 3 clinical trials for the treatment of suspected acute myocardial infarction (AMI, or heart attack). It is not yet FDA-approved or available by prescription in the US or anywhere else. There is currently no patient assistance program (PAP) from Idorsia Ltd, the manufacturer, because the drug is not marketed. This guide provides general information on what to expect when selatogrel becomes available and typical PAP structures. Contact Idorsia directly for updates on availability or future programs.

About Selatogrel

Selatogrel is a potent, fast-acting, reversible P2Y12 receptor antagonist developed by Idorsia Ltd for self-administration via subcutaneous injection using a device like the QuickShot auto-injector. It aims to provide rapid platelet inhibition (within 15 minutes, lasting 4-8 hours) when heart attack symptoms first appear, potentially improving outcomes for high-risk patients with a history of AMI. Phase 2 trials showed it was safe and well-tolerated, and Phase 3 (SOS-AMI study) is ongoing with ~14,000 patients to confirm efficacy in reducing death or non-fatal AMI.[1][2][3][6][7][8] Patients would be trained to self-administer at symptom onset, followed by emergency hospital care. It has FDA Fast Track designation but remains unapproved as of 2026.[1]

Who Qualifies for Patient Assistance?

Patient assistance programs (PAPs) from manufacturers like Idorsia typically help uninsured or underinsured patients afford medications. Since selatogrel has no active PAP, eligibility is hypothetical based on standard US pharmaceutical programs. Common qualifiers include:

• US residents (citizens, permanent residents, or legal aliens).
• Household income at or below 400-500% of the Federal Poverty Level (FPL) (varies by program; exact thresholds unavailable for selatogrel).
• Prescription from a licensed US physician.
• Age 18+ (pediatric eligibility rare). High-risk AMI patients may be prioritized if approved. Always verify with Idorsia when available.

Income Eligibility Breakdown

No specific income thresholds are published for selatogrel's PAP (program not launched). Below is a table of typical thresholds for similar cardiovascular drug PAPs (e.g., 400% FPL for individuals). 2026 FPL estimates used; actuals adjust annually.

Notes: Thresholds may be lower (e.g., 300% FPL) or flexible. Assets sometimes considered. Check HHS.gov for current FPL.

Insurance Requirements

Most PAPs require commercial insurance but exclude Medicare, Medicaid, VA, or Tricare patients, as government programs cover these. Uninsured or those with high copays/deductibles may qualify. If insured, PAPs often cover copays up to a cap (e.g., $5,000/year). Medicare Part D patients typically use alternative aid like Extra Help. Confirm selatogrel rules upon launch.

Step-by-Step Application Process

1. Get Prescribed: Obtain selatogrel prescription from your cardiologist. Discuss trial participation if eligible (ClinicalTrials.gov NCT04957719).[6]
2. Check Eligibility: Visit Idorsia's website or call patient services (details TBA) to confirm income/insurance.
3. Gather Documents: Proof of income (tax returns, W-2s, pay stubs), prescription, ID, insurance card (if applicable).
4. Apply: Online portal, mail, or phone (hypothetical; no current URL/phone).[applicationUrl null]
5. Submit & Wait: Processing typically 2-4 weeks.
6. Approval: Receive free/low-cost supply shipped to pharmacy/home. Idorsia contact: Check idorsia.com for US patient support.

Timeline and Delivery

• Processing: 1-4 weeks standard for PAPs.
• Delivery: Free shipping to home/pharmacy; 90-day supply common.
• Refills: Auto or reapply every 3-12 months; reauthorization often needed. For selatogrel, expect device training included.

Alternatives if Denied or Ineligible

• Clinical Trials: Enroll in SOS-AMI (14,000 patients, 250 sites).[1][6]
• Other PAPs: PAN Foundation, HealthWell Foundation for heart drugs.
• Generic P2Y12s: Clopidogrel (Plavix) cheaper alternatives.
• State Programs: Medicaid, pharmaceutical copay cards.
• NeedyMeds.org/Needypatients.org: Search tools.
• Biosimilars: None listed for selatogrel (novel drug).[biosimilarAlternatives empty]

Disclaimer

This guide is for informational purposes only and not medical/financial advice. Selatogrel is not approved; no PAP exists today. Details hypothetical based on industry standards and public data.[1-8] Consult your doctor, pharmacist, or Idorsia for personalized guidance. Program terms change; verify officially. Idorsia Ltd not affiliated with this guide. Word count: 950.